Table 3.

Comparative results using different disease-free survival definitions

Definition of disease-free survivalLetrozole, n = 2,582Placebo, n = 2,586
Protocol definition (first event of locoregional recurrence, distant relapse, or CLBC)92 (3.6%)155 (6.0%)
    Hazard ratio (95% CI), P0.58 (0.45-0.76), 0.00003
First event of locoregional recurrence or distant relapse excluding CLBC75 (2.9%)127 (4.9%)
    Hazard ratio (95% CI), P0.58 (0.44-0.77), 0.00015
First event of locoregional recurrence, distant relapse, invasive CLBC (excluding DCIS/DCIS)89 (3.5%)146 (5.7%)
    Hazard ratio (95% CI), P0.60 (0.46-0.78), 0.00013
First event of locoregional recurrence, distant relapse, or any second malignancy (including CLBC)142 (5.5%)198 (7.7%)
    Hazard ratio (95% CI), P0.71 (0.57-0.88), 0.00155
First event of locoregional recurrence, distant relapse, or death from any cause122 (4.7%)193 (7.5%)
    Hazard ratio (95% CI), P0.62 (0.49-0.78), 0.00003
First event of locoregional recurrence, distant relapse, any second malignancy, or death from any cause161 (6.2%)224 (8.7%)
    Hazard ratio (95% CI), P0.71 (0.58-0.87), 0.00080
  • NOTE: CLBC, contralateral breast cancer; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ. Analyses stratified for receptor status, nodal status, and adjuvant chemotherapy are summarized.